Literature DB >> 9041351

Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. Women and Infants Transmission Study (WITS).

L A Kalish1, J Pitt, J Lew, S Landesman, C Diaz, R Hershow, F B Hollinger, M Pagano, V Smeriglio, J Moye.   

Abstract

It has been suggested that a positive diagnostic test for human immunodeficiency virus type 1 (HIV-1) during the first 48 h of life is indicative of intrauterine transmission, whereas negative tests during the first week with positive tests later indicate intrapartum transmission. On the basis of data from all 140 infected infants in the Women and Infants Transmission Study (WITS), the probability was estimated that an HIV-1 culture would be positive for the first time at each day of life if cultures were performed daily. The estimated probabilities (+/-SE) by days 0, 2, 4, 7, 9, 16, and 30 of life are 27.4% (+/-6.4%), 27.4% (+/-13.0%), 45.3% (+/-20.5%), 45.3% (+/-22.5%), 65.3% (+/-20.0%), 88.4% (+/-7.8%), and 89.3% (+/-7.0%), respectively. The initial 27% probability is consistent with the hypothesis that transmission usually occurs during the intrapartum period. However, the distribution of age at first positive culture does not separate clearly into two distinct intervals. More definitive methods for determining the timing of transmission are needed.

Entities:  

Mesh:

Year:  1997        PMID: 9041351     DOI: 10.1093/infdis/175.3.712

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  Prevention of perinatal HIV transmission: current status and future developments in anti-retroviral therapy.

Authors:  Athena P Kourtis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.

Authors:  C C Tsai; P Emau; K E Follis; T W Beck; R E Benveniste; N Bischofberger; J D Lifson; W R Morton
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 3.  Options for prevention of HIV transmission from mother to child, with a focus on developing countries.

Authors:  Louise Kuhn; Ingrid Peterson
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs.

Authors:  Caroline Mitchell; Sandra Dross; Ingrid A Beck; Mark A Micek; Lisa M Frenkel
Journal:  Clin Infect Dis       Date:  2014-02-05       Impact factor: 9.079

Review 5.  The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection.

Authors:  S Maddocks; D Dwyer
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  The pharmacological treatment of acute HIV infections in neonates.

Authors:  Louise Kuhn; Stephanie Shiau
Journal:  Expert Rev Clin Pharmacol       Date:  2017-11-03       Impact factor: 5.045

Review 7.  Perinatal transmission of HIV and diagnosis of HIV infection in infants: a review.

Authors:  C B Nourse; K M Butler
Journal:  Ir J Med Sci       Date:  1998 Jan-Mar       Impact factor: 1.568

8.  Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding.

Authors:  Ivona Pandrea; Richard Onanga; Sandrine Souquiere; Augustin Mouinga-Ondéme; Olivier Bourry; Maria Makuwa; Pierre Rouquet; Guido Silvestri; François Simon; Pierre Roques; Cristian Apetrei
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

9.  Problems in Diagnosis of HIV Infection in Babies.

Authors:  A K Praharaj
Journal:  Med J Armed Forces India       Date:  2011-07-21

10.  Fetal cord blood mononuclear cells that are collected at term from HIV-1 infected women harbor transcriptionally active integrated proviral DNA.

Authors:  Jane E Ellis; Gregory A Hair; Michael K Lindsay; Aftab A Ansari; J Bruce Sundstrom
Journal:  Am J Obstet Gynecol       Date:  2007-10       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.